Loading...
XNASHRTX
Market cap223mUSD
Jan 14, Last price  
1.47USD
1D
-4.55%
1Q
-21.39%
Jan 2017
-88.78%
Name

Heron Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:HRTX chart
P/E
—
P/S
1.76
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.54%
Rev. gr., 5y
10.40%
Revenues
127m
+17.99%
5,404,0005,391,0000412,000369,0001,261,0001,301,000646,00000001,279,00030,767,00077,474,000145,968,00088,638,00086,346,000107,672,000127,044,000
Net income
-111m
L-17.81%
-9,221,000-8,210,0005,266,000-20,163,000-23,125,000-10,028,000-7,346,000-11,814,000-23,348,000-55,283,000-76,367,000-97,591,000-173,143,000-197,484,000-178,840,000-204,749,000-224,431,000-217,662,000-134,516,000-110,559,000
CFO
-59m
L-59.98%
-7,743,000-7,527,0009,181,000-17,281,000-24,275,000-10,999,000-5,483,000-7,721,000-17,009,000-40,763,000-60,282,000-78,526,000-134,097,000-170,300,000-191,805,000-124,580,000-184,820,000-203,354,000-146,912,000-58,789,000
Earnings
Mar 10, 2025

Profile

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
URL
https://www.herontx.com/
IPO date
Aug 26, 1987
Employees
203
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
127,044
17.99%
107,672
24.70%
Cost of revenue
237,659
282,330
Unusual Expense (Income)
NOPBT
(110,615)
(174,658)
NOPBT Margin
Operating Taxes
(47,508)
Tax Rate
NOPAT
(110,615)
(127,150)
Net income
(110,559)
-17.81%
(134,516)
-38.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
29,755
75,059
BB yield
-12.67%
-27.58%
Debt
Debt current
6,150
2,694
Long-term debt
182,428
162,976
Deferred revenue
Other long-term liabilities
241
241
Net debt
108,169
80,818
Cash flow
Cash from operating activities
(58,789)
(146,912)
CAPEX
(1,545)
(1,825)
Cash from investing activities
17,995
(3,324)
Cash from financing activities
54,107
75,059
FCF
(100,322)
(136,112)
Balance
Cash
80,409
84,852
Long term investments
Excess cash
74,057
79,468
Stockholders' equity
(1,904,498)
(1,794,283)
Invested Capital
2,053,469
1,965,573
ROIC
ROCE
EV
Common stock shares outstanding
138,135
108,876
Price
1.70
-32.00%
2.50
-72.62%
Market cap
234,830
-13.73%
272,190
-69.72%
EV
342,998
353,008
EBITDA
(107,716)
(171,769)
EV/EBITDA
Interest
3,868
2,474
Interest/NOPBT